Pila Pharma AB (publ) (STO:PILA)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.182
-0.064 (-5.14%)
At close: Mar 6, 2026
-68.48%
Market Cap 54.00M
Revenue (ttm) 1.13M
Net Income (ttm) -16.86M
Shares Out 45.68M
EPS (ttm) -0.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 109,741
Average Volume 116,933
Open 1.248
Previous Close 1.246
Day's Range 1.126 - 1.248
52-Week Range 1.024 - 4.095
Beta 0.21
RSI 41.86
Earnings Date Feb 10, 2026

About Pila Pharma AB

Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is headquartered in Malmö, Sweden. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 1
Stock Exchange Nasdaq Stockholm
Ticker Symbol PILA
Full Company Profile

Financial Performance

In 2025, Pila Pharma AB's revenue was 1.13 million, an increase of 42.68% compared to the previous year's 789,889. Losses were -16.86 million, 50.0% more than in 2024.

Financial Statements

News

There is no news available yet.